Skip to Content
Søg Menu

Promising Results from EHA23: Gilteritinib as Posttransplant Maintenance Therapy for FLT3-ITD AML Patients

New data presented at EHA23 indicates the potential of gilteritinib in eradicating minimal residual disease and its implications for improving outcomes in high-risk AML patients.

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Drug Sensitivity Screening to Guide Clinical Decisions for Hematologic Cancers

/ Sigrid S. Skånland
AMLCLL
Jad Othman

MRD Status in NPM1 Mutated AML Should Be a Part of the Selection of Patients for Transplant in First Remission

/ Jad Othman
ASH23AML Play the Video 03:32

ASH 2023: Oral Decitabine-Cedazuridine Tablet Shows Promise for AML Treatment in Phase III Study

/ BestPractice Nordic
ASH23AML
Sergio Giralt

In the Era of Personalized Treatment and Targeted Therapies

/ Sergio Giralt
ASH23AML Play the Video 2:46
Carsten Niemann

Overlevelsesgevinst for skrøbelige CLL-patienter i behandling med Imbruvica og Venclyxto

/ Carsten Utoft Niemann
EHA23CLL Play the Video 3:35
Anna Sureda Balari

Epcoritamab with Rituximab and Lenalidomide (R2) for Patients with High-Risk Follicular Lymphoma

/ Anna Sureda Balari
EHA23Lymfom Play the Video 6:24
Mark Levis

Gilteritinib for Patients with Newly Diagnosed AML

/ Mark Levis
EHA23Ernæring Play the Video 9:04
Arnon Kater

MURANO Study Supports the Use of Fixed-Duration VenR in R/R CLL

/ Arnon Kater
EHA23CLL Play the Video 10:51
Evangelos Terpos

Daratumumab Combination Shows Positive Responses in Pretreated R/R Multiple Myeloma

/ Evangelos Terpos
EHA23Myelomatose Play the Video 6:39

Brænder du for at skrive?

Vil du gerne dele din forskning eller dine kliniske erfaringer med dine kollegaer inden for netop dit speciale? Har du en ide til en artikel, som du gerne vil udgive hos os? Send redaktionen en mail på redaktion@bpno.dk

Send mail til redaktionen
Back to top